Healio nAMD, DME, and DR: Current Approaches in Reducing Treatment Burden
Neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) are prevalent retinal conditions that significantly impact vision worldwide. High treatment burden involving frequent intravitreal injections poses a significant barrier to treatment adherence and improved patient outcomes. Advances in anti-vascular endothelial growth factor (VEGF) treatment strategies aim to extend dosing intervals while maintaining efficacy, improving treatment adherence and patient satisfaction. This program equips comprehensive ophthalmologists with the latest data on current and emerging therapies for nAMD, DME, and DR that promise to reduce treatment burden. Expert faculty discuss real-world evidence and personalized approaches to optimize fluid control, reduce injection frequency, and enhance visual and anatomical outcomes.
Cost: Free
View Offer chevron_rightDetails
Neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) are prevalent retinal conditions that significantly impact vision worldwide. High treatment burden involving frequent intravitreal injections poses a significant barrier to treatment adherence and improved patient outcomes. Advances in anti-vascular endothelial growth factor (VEGF) treatment strategies aim to extend dosing intervals while maintaining efficacy, improving treatment adherence and patient satisfaction. This program equips comprehensive ophthalmologists with the latest data on current and emerging therapies for nAMD, DME, and DR that promise to reduce treatment burden. Expert faculty discuss real-world evidence and personalized approaches to optimize fluid control, reduce injection frequency, and enhance visual and anatomical outcomes.
Topics Covered
nAMD, DME, and DR
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Incorporate nAMD therapies that offer high efficacy and longer intervals between doses.
- Apply the latest data on available and emerging agents for treating patients with DME and /DR that maintain efficacy while minimizing dosing frequency.
Target Audience
The intended audience for this activity is comprehensive ophthalmologists and other healthcare professionals involved in the management of patients with nAMD, DME, and DR.
Additional credit info
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.